CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 target
Drug / intervention
13C-Methacetin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00244569
NCT00244569Phase 3Completed
CompareCT.gov

Development of a Breath Test for Monitoring Liver Metabolic Function in Patients With Chronic Liver Disease and Cirrhosis

Virginia Commonwealth University·interventional·Posted Oct 26, 2005·Updated Mar 20, 2017

In Brief

A Phase 3 clinical trial evaluating 13C-Methacetin and Breath ID Machine for Fatty Liver and Cirrhosis. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of the Oridion Breath ID machine in monitoring liver metabolic functions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFatty Liver, Cirrhosis
CountriesUnited States
CollaboratorsOridion

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 26, 2005
Enrollment StartSep 1, 2005
Primary CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 20.7 years ago

Interventions

13C-Methacetindrug

Breath ID Machinedevice